PPP6R2

Summary

PPP6R2 (protein phosphatase 6 regulatory subunit 2, HGNC:19253) is a protein-coding gene on chromosome 22q13.33, encoding Serine/threonine-protein phosphatase 6 regulatory subunit 2 (O75170). Regulatory subunit of protein phosphatase 6 (PP6).

The protein encoded by this gene is a regulatory protein for the protein phosphatase-6 catalytic subunit. Together, these proteins act as a significant T-loop phosphatase for Aurora A, an essential mitotic kinase. Loss of function of either the regulatory or catalytic subunit of protein phosphatase-6 interferes with spindle formation and chromosome alignment.

Source: NCBI Gene 9701 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 194 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001242898

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19253
Approved symbol	PPP6R2
Name	protein phosphatase 6 regulatory subunit 2
Location	22q13.33
Locus type	gene with protein product
Status	Approved
Aliases	dJ579N16.1, SAP190
Ensembl gene	ENSG00000100239
Ensembl biotype	protein_coding
OMIM	610877
Entrez	9701

Gene structure

Transcript identifiers

Ensembl transcripts: 86 — 84 protein_coding, 2 retained_intron

ENST00000216061, ENST00000359139, ENST00000395741, ENST00000395744, ENST00000401672, ENST00000427222, ENST00000470046, ENST00000473283, ENST00000612753, ENST00000906613, ENST00000906614, ENST00000906615, ENST00000906616, ENST00000906617, ENST00000906618, ENST00000906619, ENST00000906620, ENST00000906621, ENST00000906622, ENST00000906623, ENST00000906624, ENST00000906625, ENST00000906626, ENST00000906627, ENST00000906628, ENST00000906629, ENST00000906630, ENST00000906631, ENST00000906632, ENST00000906633, ENST00000906634, ENST00000906635, ENST00000906636, ENST00000906637, ENST00000906638, ENST00000906639, ENST00000906640, ENST00000906641, ENST00000906642, ENST00000906643, ENST00000906644, ENST00000906645, ENST00000906646, ENST00000906647, ENST00000906648, ENST00000906649, ENST00000906650, ENST00000906651, ENST00000906652, ENST00000906653, ENST00000906654, ENST00000938136, ENST00000938137, ENST00000938138, ENST00000938139, ENST00000938140, ENST00000938141, ENST00000938142, ENST00000966964, ENST00000966965, ENST00000966966, ENST00000966967, ENST00000966968, ENST00000966969, ENST00000966970, ENST00000966971, ENST00000966972, ENST00000966973, ENST00000966974, ENST00000966975, ENST00000966976, ENST00000966977, ENST00000966978, ENST00000966979, ENST00000966980, ENST00000966981, ENST00000966982, ENST00000966983, ENST00000966984, ENST00000966985, ENST00000966986, ENST00000966987, ENST00000966988, ENST00000966989, ENST00000966990, ENST00000966991

RefSeq mRNA: 13 — MANE Select: NM_001242898 NM_001242898, NM_001242899, NM_001242900, NM_001351641, NM_001351642, NM_001351643, NM_001351644, NM_001351645, NM_001351646, NM_001351647, NM_001351648, NM_001365836, NM_014678

CCDS: CCDS33681, CCDS56235, CCDS56236, CCDS74881, CCDS93184

Canonical transcript exons

ENST00000612753 — 24 exons

Exon	Start	End
ENSE00001363026	50372020	50372150
ENSE00003743564	50343327	50343550
ENSE00003754055	50444199	50445090
ENSE00003888750	50440822	50441026
ENSE00003888759	50439701	50439857
ENSE00003889134	50406689	50406875
ENSE00003889498	50434966	50435081
ENSE00003890531	50422254	50422380
ENSE00003890758	50419349	50419462
ENSE00003891344	50438599	50438762
ENSE00003891518	50416092	50416157
ENSE00003892246	50431173	50431382
ENSE00003892815	50423462	50423614
ENSE00003893045	50432265	50432329
ENSE00003893216	50439961	50440049
ENSE00003893354	50436988	50437068
ENSE00003893516	50393893	50394135
ENSE00003893642	50436367	50436452
ENSE00003895035	50437506	50437603
ENSE00003895163	50438174	50438298
ENSE00003895170	50418867	50418979
ENSE00003895249	50414552	50414689
ENSE00003895359	50443866	50444117
ENSE00003896029	50437843	50437900

Expression profiles

Bgee: expression breadth ubiquitous, 274 present calls, max score 97.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 35.4414 / max 238.3430, expressed in 1820 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
192991	32.8926	1820
192992	2.4786	1410
192993	0.0701	23

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.37	gold quality
cerebellar hemisphere	UBERON:0002245	97.06	gold quality
cerebellar cortex	UBERON:0002129	96.95	gold quality
left testis	UBERON:0004533	96.75	gold quality
right testis	UBERON:0004534	96.66	gold quality
right lobe of liver	UBERON:0001114	96.65	gold quality
adenohypophysis	UBERON:0002196	96.64	gold quality
right lobe of thyroid gland	UBERON:0001119	95.91	gold quality
metanephros cortex	UBERON:0010533	95.81	gold quality
cerebellum	UBERON:0002037	95.51	gold quality
apex of heart	UBERON:0002098	95.48	gold quality
right adrenal gland cortex	UBERON:0035827	95.47	gold quality
left lobe of thyroid gland	UBERON:0001120	95.44	gold quality
right adrenal gland	UBERON:0001233	95.28	gold quality
pituitary gland	UBERON:0000007	95.26	gold quality
body of stomach	UBERON:0001161	95.02	gold quality
right frontal lobe	UBERON:0002810	94.93	gold quality
left adrenal gland cortex	UBERON:0035825	94.85	gold quality
lower esophagus mucosa	UBERON:0035834	94.85	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.76	gold quality
left adrenal gland	UBERON:0001234	94.66	gold quality
gastrocnemius	UBERON:0001388	94.63	gold quality
mucosa of stomach	UBERON:0001199	94.59	gold quality
right uterine tube	UBERON:0001302	94.57	gold quality
right ovary	UBERON:0002118	94.57	gold quality
endocervix	UBERON:0000458	94.49	gold quality
body of uterus	UBERON:0009853	94.46	gold quality
granulocyte	CL:0000094	94.42	gold quality
thyroid gland	UBERON:0002046	94.35	gold quality
minor salivary gland	UBERON:0001830	94.21	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.83
E-MTAB-6058	no	175.47

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting PPP6R2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-4711-5P	98.89	68.00	965

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppp6r2a	ENSDARG00000045540
danio_rerio	ppp6r2b	ENSDARG00000069654
mus_musculus	Ppp6r2	ENSMUSG00000036561
rattus_norvegicus	Ppp6r2	ENSRNOG00000026425
drosophila_melanogaster	fmt	FBGN0035688
caenorhabditis_elegans		WBGENE00008166

Paralogs (2): PPP6R1 (ENSG00000105063), PPP6R3 (ENSG00000110075)

Protein

Protein identifiers

Serine/threonine-protein phosphatase 6 regulatory subunit 2 — O75170 (reviewed: O75170)

Alternative names: SAPS domain family member 2

All UniProt accessions (3): O75170, A0A0A0MSJ8, T1ECW5

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory subunit of protein phosphatase 6 (PP6). May function as a scaffolding PP6 subunit. Involved in the PP6-mediated dephosphorylation of NFKBIE opposing its degradation in response to TNF.

Subunit / interactions. Protein phosphatase 6 (PP6) holoenzyme is proposed to be a heterotrimeric complex formed by the catalytic subunit, a SAPS domain-containing subunit (PP6R) and an ankyrin repeat-domain containing regulatory subunit (ARS). Interacts with PPP6C and NFKBIE. Interacts with ANKRD28.

Subcellular location. Cytoplasm.

Tissue specificity. Ubiquitously expressed with strongest expression in the testis followed by liver, heart, kidney, brain and placenta.

Similarity. Belongs to the SAPS family.

Isoforms (6)

UniProt ID	Names	Canonical?
O75170-1	1	yes
O75170-2	2
O75170-3	3
O75170-4	4
O75170-5	5
O75170-6	6

RefSeq proteins (13): NP_001229827, NP_001229828, NP_001229829, NP_001338570, NP_001338571, NP_001338572, NP_001338573, NP_001338574, NP_001338575, NP_001338576, NP_001338577, NP_001352765, NP_055493 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007587	SAPS	Family
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily

Pfam: PF04499

UniProt features (20 total): splice variant 6, region of interest 3, sequence conflict 3, modified residue 3, sequence variant 2, compositionally biased region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75170-F1	66.00	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 289, 771, 828

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 136 (showing top): ACTACCT_MIR196A_MIR196B, TGCACTT_MIR519C_MIR519B_MIR519A, BROWNE_HCMV_INFECTION_48HR_DN, ROZANOV_MMP14_TARGETS_UP, MORF_EPHA7, MORF_BMPR2, MODULE_11, MODULE_60, TGCCTTA_MIR124A, MODULE_38, AP2_Q6_01, TTTGCAC_MIR19A_MIR19B, MORF_DCC, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN

GO Biological Process (1): regulation of signal transduction (GO:0009966)

GO Molecular Function (3): protein phosphatase regulator activity (GO:0019888), protein phosphatase binding (GO:0019903), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytosol (GO:0005829), cytoplasmic ribonucleoprotein granule (GO:0036464), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
cellular anatomical structure	2
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
phosphoprotein phosphatase activity	1
phosphatase regulator activity	1
protein phosphatase binding	1
phosphatase binding	1
binding	1
intracellular membrane-bounded organelle	1
ribonucleoprotein granule	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1190 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP6R2	PPP6C	O00743	954
PPP6R2	SF3B1	O75533	923
PPP6R2	NFKBIE	O00221	827
PPP6R2	PPP2CA	P05323	733
PPP6R2	ANKRD44	Q8N8A2	713
PPP6R2	DPH3	Q96FX2	682
PPP6R2	ANKRD52	Q8NB46	657
PPP6R2	KTI12	Q96EK9	632
PPP6R2	ANKRD28	O15084	621
PPP6R2	PPP4R2	Q9NY27	599
PPP6R2	PPP4R1	Q8TF05	579
PPP6R2	PPP4C	P33172	576
PPP6R2	ELP6	Q0PNE2	548
PPP6R2	PPP6R3	Q5H9R7	502
PPP6R2	DIPK1A	Q5T7M9	493

IntAct

91 interactions, top by confidence:

A	B	Type	Score
PPP6C	ANKRD28	psi-mi:“MI:0914”(association)	0.870
PPP6C	PPP6R2	psi-mi:“MI:0915”(physical association)	0.870
ANKRD28	PPP6C	psi-mi:“MI:0914”(association)	0.870
PPP6R2	PPP6C	psi-mi:“MI:0914”(association)	0.870
ANKRD52	PPP6C	psi-mi:“MI:0914”(association)	0.790
PLK1	SPAG9	psi-mi:“MI:0914”(association)	0.790
ANKRD44	PPP6C	psi-mi:“MI:0914”(association)	0.790
PPP6R2	ANKRD28	psi-mi:“MI:0915”(physical association)	0.760
ANKRD44	ANKRD28	psi-mi:“MI:0914”(association)	0.710
USP10	ANKRD28	psi-mi:“MI:0914”(association)	0.610
SDCBP	PPP6R2	psi-mi:“MI:0407”(direct interaction)	0.590
NFKBIE	PPP6R2	psi-mi:“MI:0915”(physical association)	0.590
PLK1	C1orf226	psi-mi:“MI:0914”(association)	0.560
PLK1	PPP6C	psi-mi:“MI:0914”(association)	0.530
GORASP1	PPP6R2	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
AURKA	WDR62	psi-mi:“MI:0914”(association)	0.530
PDGFRL	ANKRD28	psi-mi:“MI:0914”(association)	0.530
PIP	TBKBP1	psi-mi:“MI:0914”(association)	0.530
SDCBP	TARS3	psi-mi:“MI:0914”(association)	0.530

BioGRID (205): PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS), PPP6R2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M9QN10, A1X157, A7E305, B0BF33, B3MSI4, B4F6W9, E1B7Q7, F1LP64, F1RCR6, G3X9J0, G5E870, O60292, O75170, O95155, P42858, P42859, P51112, P70478, Q07DW4, Q07DY4, Q07DZ5, Q07E41, Q08AE8, Q09YJ3, Q09YK4, Q09YM8, Q108T9, Q14669, Q1L8G6, Q1LUT1, Q1LVK9, Q2NL16, Q2QLB3, Q2QLF8, Q2V2M9, Q3UJB9, Q3ZAV8, Q6I6G8, Q6P2E9, Q6P2L6

Diamond homologs: O75170, Q5F471, Q5H9R7, Q6NRF1, Q6NRI0, Q7TSI3, Q8R3Q2, Q922D4, Q9UPN7, B5VMH6, C8ZCJ2, P36123, P40856

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CDK1	“down-regulates activity”	PPP6R2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

194 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	144
Likely benign	17
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3062449	GRCh37/hg19 22q13.2-13.33(chr22:44034281-51197838)x1	Pathogenic

SpliceAI

5712 predictions. Top by Δscore:

Variant	Effect	Δscore
22:50343546:GGCAG:G	donor_gain	1.0000
22:50343547:GCAG:G	donor_gain	1.0000
22:50343547:GCAGG:G	donor_gain	1.0000
22:50343551:GTG:G	donor_loss	1.0000
22:50372148:AAGGT:A	donor_loss	1.0000
22:50372150:GGT:G	donor_loss	1.0000
22:50372151:G:GA	donor_loss	1.0000
22:50394136:G:GG	donor_gain	1.0000
22:50414678:G:GT	donor_gain	1.0000
22:50414686:GCAC:G	donor_gain	1.0000
22:50414688:AC:A	donor_gain	1.0000
22:50414690:G:GG	donor_gain	1.0000
22:50414690:GT:G	donor_loss	1.0000
22:50414691:T:A	donor_loss	1.0000
22:50414694:G:GG	donor_gain	1.0000
22:50416088:TCA:T	acceptor_loss	1.0000
22:50416089:CAG:C	acceptor_loss	1.0000
22:50416090:A:AG	acceptor_gain	1.0000
22:50416090:AG:A	acceptor_loss	1.0000
22:50416090:AGT:A	acceptor_gain	1.0000
22:50416090:AGTG:A	acceptor_gain	1.0000
22:50416091:G:GA	acceptor_gain	1.0000
22:50416091:GT:G	acceptor_gain	1.0000
22:50416091:GTG:G	acceptor_gain	1.0000
22:50416091:GTGG:G	acceptor_gain	1.0000
22:50416091:GTGGC:G	acceptor_gain	1.0000
22:50416155:GAT:G	donor_gain	1.0000
22:50416158:G:GG	donor_gain	1.0000
22:50416158:G:T	donor_loss	1.0000
22:50416159:T:A	donor_loss	1.0000

AlphaMissense

6341 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:50393912:T:C	F2L	0.999
22:50393914:C:A	F2L	0.999
22:50393914:C:G	F2L	0.999
22:50393915:T:A	W3R	0.999
22:50393915:T:C	W3R	0.999
22:50393917:G:C	W3C	0.999
22:50393917:G:T	W3C	0.999
22:50394022:G:C	K38N	0.999
22:50394022:G:T	K38N	0.999
22:50406712:T:C	L84P	0.999
22:50406825:A:C	S122R	0.999
22:50406827:T:A	S122R	0.999
22:50406827:T:G	S122R	0.999
22:50406834:A:C	S125R	0.999
22:50406836:C:A	S125R	0.999
22:50406836:C:G	S125R	0.999
22:50406839:G:C	K126N	0.999
22:50406839:G:T	K126N	0.999
22:50431198:A:T	N384I	0.999
22:50431199:T:A	N384K	0.999
22:50431199:T:G	N384K	0.999
22:50431202:C:A	N385K	0.999
22:50431202:C:G	N385K	0.999
22:50435004:T:C	L480P	0.999
22:50436393:T:A	W515R	0.999
22:50436393:T:C	W515R	0.999
22:50393913:T:C	F2S	0.998
22:50393913:T:G	F2C	0.998
22:50394131:T:C	F75L	0.998
22:50394133:C:A	F75L	0.998

dbSNP variants (sampled 300 via entrez): RS1000032933 (22:50337351 G>A,C,T), RS1000033269 (22:50429458 A>G), RS1000062128 (22:50424417 C>A,T), RS1000088850 (22:50343558 C>A,T), RS1000110499 (22:50392534 C>T), RS1000157492 (22:50386050 C>G), RS1000176545 (22:50391319 A>C,G), RS1000211251 (22:50385774 C>G), RS1000249163 (22:50386969 C>G,T), RS1000270746 (22:50351615 A>G,T), RS1000282090 (22:50355953 T>C), RS1000295598 (22:50348815 C>G,T), RS1000309068 (22:50370442 C>A,T), RS1000314998 (22:50423153 G>A), RS1000320508 (22:50337562 CTGTG>C,CTG)

Disease associations

OMIM: gene MIM:610877 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST002481_12	Acne (severe)	4.000000e-06
GCST006612_125	LDL cholesterol	5.000000e-08
GCST006979_837	Heel bone mineral density	4.000000e-16
GCST007429_92	Lung function (FVC)	5.000000e-07
GCST007430_66	Peak expiratory flow	9.000000e-06
GCST007432_102	FEV1	1.000000e-09
GCST010204_149	Low density lipoprotein cholesterol levels	9.000000e-10
GCST010243_22	Apolipoprotein B levels	4.000000e-13
GCST010245_46	LDL cholesterol levels	4.000000e-09

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0009270	heel bone mineral density
EFO:0004312	vital capacity
EFO:0009718	peak expiratory flow
EFO:0004314	forced expiratory volume
EFO:0004615	apolipoprotein B measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105960 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
Cyclosporine	decreases expression	2
FR900359	increases phosphorylation	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
manganese chloride	decreases expression, increases abundance	1
isobutyl alcohol	increases abundance, affects cotreatment, decreases expression	1
CGP 52608	increases reaction, affects binding	1
Air Pollutants	affects expression, increases abundance	1
Benzo(a)pyrene	decreases expression	1
Caffeine	affects phosphorylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Manganese	decreases expression, increases abundance	1
Ozone	affects expression, increases abundance	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Quercetin	decreases expression	1
Selenium	affects cotreatment, increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Vitamin E	affects cotreatment, increases expression	1
Aflatoxin B1	decreases expression, increases methylation	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1
1-Butanol	decreases expression, increases abundance, affects cotreatment	1
Acrylamide	decreases expression	1
Particulate Matter	affects cotreatment, decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4012583	Binding	Binding affinity to PP6R2 protein in human INA-6 cells after 3 hrs by nanoLC-MS/MS method	Ugi Reaction-Derived α-Acyl Aminocarboxamides Bind to Phosphatidylinositol 3-Kinase-Related Kinases, Inhibit HSF1-Dependent Heat Shock Response, and Induce Apoptosis in Multiple Myeloma Cells. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TG32	HAP1 PPP6R2 (-) 1	Cancer cell line	Male
CVCL_TG33	HAP1 PPP6R2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer